Choosing the Right Clinical Trial Sites: A Practical Selection Checklist

Selecting the wrong sites is one of the most expensive mistakes in a clinical trial.

Delays in enrollment, protocol deviations, and operational issues often come from one early decision: activating sites that were not ready to deliver.

With increasing protocol complexity and global competition for patients, site selection is no longer a formality. It directly impacts timelines, costs, and study outcomes.

Why It Matters

Clinical trial timelines are heavily influenced by site performance.

Even a small number of underperforming sites can slow enrollment, increase monitoring costs, and affect data quality.

In practice, a minority of sites usually deliver the majority of enrollments. The challenge is identifying them early.

Where It Fails

Most issues come from how feasibility is assessed, not from a lack of data.

• Relying on past relationships: Sites are often selected based on previous collaborations instead of current capacity or relevance.

• Overestimating recruitment: Enrollment projections tend to be optimistic without validating real patient availability.

• Missing operational constraints: Factors like staffing, competing studies, or startup timelines are often underestimated.

Research from organizations such as the National Institutes of Health shows that inaccurate feasibility is a leading cause of enrollment delays.

What to Evaluate

A strong site selection process looks at multiple dimensions together.

Having patients in a region does not mean having eligible patients for your protocol.

Patient access

What matters is whether patients:

• meet inclusion criteria

• are actively seen at the site

• can be identified and screened quickly

This is the primary driver of enrollment performance — prioritize sites with verifiable access to eligible patients.

Operational readiness

Even strong sites can underperform if they lack capacity.

This includes staff availability, experience with similar studies, and the ability to manage visits and data.

Competing studies

Sites often run several trials at once.

Understanding where your study fits in their priorities can directly impact recruitment.

Startup timelines

Delays often come from ethics approvals, contracts, and administrative processes.

These are predictable but frequently underestimated.

Enrollment Forecasts

Enrollment projections often fail because they are based on expectations, not evidence.

Sites may express confidence, but projections remain unreliable without validating:

• patient flow
• screening rates
• past performance

Grounding forecasts in real data is key.

Risk Reduction

Many risks are visible before activation.

• Early signals: Common indicators include limited staff, inconsistent performance, or infrastructure gaps.

• Acting early: Identifying these issues before activation helps avoid delays and costly adjustments later.

Team Alignment

Site selection involves multiple teams with different priorities.

• Shared criteria: A structured approach ensures sites are evaluated consistently.

• Faster decisions: Clear criteria reduce internal friction and make decisions easier to justify.

A Competitive Advantage

Strong trials are built on strong sites.

Activating fewer, better-performing sites can improve timelines, reduce risk, and increase data quality.

Site selection, when done well, becomes a competitive advantage.

Make better site decisions

Site performance depends on more than experience. It depends on whether eligible patients are actually reachable.

At PatLynk, we connect site selection with real patient availability through pre-screening.

Connect with us on LinkedIn, or explore our pre-screening to understand where recruitment is truly feasible.